医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Daewoong Pharmaceutical Welcomes ITC Decision to Review Judge’s Initial Determination

2020年09月22日 PM08:31
このエントリーをはてなブックマークに追加


 

SEOUL

Daewoong Pharmaceutical Co., Ltd. today commented on the decision by the United States International Trade Commission to comprehensively reconsider a judge’s initial determination in the case.

Daewoong and its partner Evolus, Inc. contend the judge’s initial determination contained significant legal and factual errors and, if adopted as final by the ITC, risks setting dangerous policy precedents. The ITC has announced it will review several issues as requested by Daewoong and Evolus, including subject matter jurisdiction, standing, trade secret existence and misappropriation, and domestic industry. As part of its review process, the ITC has solicited comments on the public interest implications relating to the issues under review. The ultimate outcome of the ITC’s review could be a reversal or shortening of the 10-year import ban that was initially recommended by the judge.

Daewoong issued the following comment on the ITC’s decision:

“We are pleased that the ITC agreed with us and the more than 70 top trade secrets experts, economists, free-market think tanks and doctors who urged the ITC to review this case. Reversing the judge on key findings on which he based a misguided 10-year import ban would not only be a victory for Daewoong and our U.S.-based partner Evolus, but also for American consumers, doctors, innovation and competition. In the meantime, Jeuveau remains available to U.S. consumers who are increasingly choosing it for its advantages over Botox.

Daewoong looks forward to briefing these issues, and to a robust discussion of the dangerous public interest implications of the initial determination.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005539/en/

CONTACT

Media

Trent Duffy / Scott Lindlaw / Reze Wong / Celia de Pentheny O’Kelly

Daewoong-SVC@sardverb.com

202.318.3800 / 415.618.8750

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Take ‘VOW’ to Protect All Humanity: ‘Vaccinate Our World!’
  • 太平洋電気通信協議会が第44回年次総会の参加募集を発表
  • アビオメッド、ImpellaのPROTECT IVランダム化対照試験に最初の患者を組み入れたことを発表
  • Prestige Biopharma’s New Vaccine Production Centre for Infectious Diseases Including COVID-19
  • Pacific Telecommunications Council Announces the Call for Participation for Its 44th Annual Conference